Cargando…
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
BACKGROUND: Wilms’ tumor 1 (WT1) is overexpressed in various malignancies. DSP-7888 Dosing Emulsion, also known as ombipepimut-S (United States Adopted Name; International Nonproprietary Name: adegramotide/nelatimotide), is an investigational therapeutic cancer vaccine comprising two synthetic pepti...
Autores principales: | Spira, Alexander, Hansen, Aaron R., Harb, Wael A., Curtis, Kelly K., Koga-Yamakawa, Erina, Origuchi, Makoto, Li, Zhonggai, Ertik, Bella, Shaib, Walid L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266707/ https://www.ncbi.nlm.nih.gov/pubmed/33939067 http://dx.doi.org/10.1007/s11523-021-00813-6 |
Ejemplares similares
-
Phase 1/2 study evaluating the safety and efficacy of DSP‐7888 dosing emulsion in myelodysplastic syndromes
por: Ueda, Yasunori, et al.
Publicado: (2022) -
Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors
por: Suginobe, Natsuko, et al.
Publicado: (2022) -
DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects
por: Ota, Yosuke, et al.
Publicado: (2023) -
EE-7888. Campaña de captación (catch-up) con COVID-19 en gestantes: implementación y resultados
por: Fernández-Prada, M., et al.
Publicado: (2022) -
DSP review and applications
por: Crosetto, D
Publicado: (1990)